Fig. 3
From: EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers
Validation of the predictive value of EPHA7-MUT. a The Kaplan-Meier curves comparing OS between EPHA7-MUT and EPHA7-WT patients in the validation cohort. b The Kaplan-Meier curves comparing OS between EPHA7-MUT and EPHA7-WT patients in the non-ICI-treated cohort. c The Kaplan-Meier curves comparing OS between EPHA7-MUT and EPHA7-WT patients in TCGA cohort. d Forest plot depicting subgroup analysis in the validation cohort. Drug class “Combination” indicated combination therapy of CTLA-4 and PD-(L)1 antibodies. EPHA7-MUT cases were insufficient for hazard ratio calculation in ESCA and glioma subgroups. There were only 694 patients with available CNA data for survival analysis. NSCLC, non-small cell lung cancer; SKCM, melanoma; HNSC, head and neck cancer; CRC, colorectal cancer; BLCA, bladder cancer; ESCA, esophagogastric cancer. e The Kaplan-Meier curves comparing OS among EPHA7MUTTMBhigh, EPHA7MUTTMBlow, EPHA7WTTMBhigh, and EPHA7WTTMBlow groups in the validation cohort. f The Kaplan-Meier curves comparing OS among EPHA7MUTCNAhigh, EPHA7MUTCNAlow, EPHA7WTCNAhigh, and EPHA7WTCNAlow groups in the validation cohort. HR and adjusted P were calculated by the Cox proportional hazards regression analysis. Available confounding factors were adjusted: validation cohort (age, sex, cancer type, drug class, TMB level), non-ICI-treated cohort (sex, cancer type, TMB level), and TCGA cohort (age, sex, race, cancer type, histology grade, tumor stage). NR indicated the median OS has not been reached